Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, and Isomorphic Labs — the AI‑first drug design and development company under Alphabet Inc. (NASDAQ: GOOGL) — announced a research collaboration that pairs Isomorphic’s artificial‑intelligence approach to drug discovery with Merck’s rich proprietary data resources and deep discovery experience. The partners will work to discover therapeutic small‑molecule candidates against an oncology target of strategic importance.
Collaboration Snapshot
| Item | Detail |
|---|---|
| Parties | Merck & Co., Inc. (NYSE: MRK) and Isomorphic Labs (Alphabet Inc., NASDAQ: GOOGL) |
| Announcement Date | 19 November 2026 |
| Deal Type | AI‑driven research collaboration |
| Focus | Discovery of small‑molecule candidates against a strategically important oncology target |
| Upfront Payment | Paid by Merck to Isomorphic Labs – amount not disclosed |
| Milestone Payments | Tied to specified research, development, regulatory and commercial milestones – amounts not disclosed |
| Royalties | Tiered royalties on net sales |
| Co‑Funding Option | Isomorphic Labs holds an option to co‑fund development activities in return for elevated royalties |
Deal Profile & AI Platform
- Platform: Isomorphic Labs’ world‑leading, modality‑agnostic Drug Design Engine (IsoDDE), comprised of foundational AI models for next‑generation drug design.
- Company Background: Founded in 2021 under the Alphabet umbrella with a mission to transform drug discovery with the power of artificial intelligence.
- Merck Contribution: The company’s proprietary data resources and deep small‑molecule discovery experience, anchoring the collaboration in validated medicinal chemistry know‑how.
- Target: An oncology target of strategic importance – specific identity not disclosed.
- Financial Structure: Upfront payment plus eligibility for milestone‑based payments across research, development, regulatory and commercial stages, and tiered royalties on net sales; the co‑funding option allows Isomorphic to share development costs in exchange for elevated royalties.
Strategic Rationale – AI in Oncology Discovery
- AI‑First Drug Design: Foundational AI models are increasingly applied to structure prediction, molecule generation and property optimization, with the potential to compress early discovery timelines relative to conventional screening campaigns.
- Oncology Priority: Cancer remains the largest therapeutic area in pharmaceutical R&D, and small molecules retain distinct advantages in oral bioavailability and intracellular target engagement.
- Partnership Model: The upfront‑plus‑milestones‑plus‑royalties structure has become a standard template as big pharma engages AI‑native platforms to diversify and accelerate pipeline generation.
Market Impact & Outlook
- For Merck: The collaboration extends the company’s external innovation strategy into AI‑native discovery, reinforcing its position in oncology, a core therapeutic franchise.
- For Isomorphic Labs: A research partnership with a leading global pharmaceutical company represents external validation of the IsoDDE platform, with the upfront payment and milestone structure providing non‑dilutive funding.
- Sector Signal: The deal underscores continued convergence between Big Pharma and AI drug discovery platforms, as major companies increasingly license or partner for artificial‑intelligence capabilities rather than build them in house.
- Next Steps: The collaboration is at the research stage; progression of any candidate into development will depend on discovery success. Timelines and program details were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the research collaboration between Merck & Co., Inc. and Isomorphic Labs, including the discovery of therapeutic candidates, milestone achievements, development timelines and commercial expectations. Actual results may differ materially due to risks inherent in early‑stage drug discovery, clinical outcomes, regulatory review and competitive dynamics.-Fineline Info & Tech
